LGD-6972 / Ligand - LARVOL DELTA

The Inferential Binding Sites of GCGR for Small Molecules Using Protein Dynamic Conformations and Crystal Structures. (PubMed, Int J Mol Sci) - "Currently, six small molecules (Bay 27-9955, MK-0893, MK-3577, LY2409021, PF-06291874, and LGD-6972) have been tested or are undergoing clinical trials, but only the binding site of MK-0893 has been resolved. Additionally, LGD-6972 exhibited relatively stable binding in Pocket 5. We also conducted structural modifications of LGD-6972 based on the results of MD simulations and predicted its analogues' bioavailability, providing a reference for the study of GCGR small molecules."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation (clinicaltrials.gov) - P1; N=8; Not yet recruiting; Sponsor: Ligand Pharmaceuticals

New P1 trial • Biosimilar • Diabetes